Recent Updates
Recently added Catalysts

X4 Pharmaceuticals, Inc.

XFORFDA catalysts, PDUFA dates & pipeline intelligence
$3.09
▲ +0.26 · +9.19%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full XFOR financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $2.4352W HIGH $4.83
Volume
1.11 M
Value Traded
3.34 M
Short % Float
10.31%
Days to Cover
10.9
-4.33%Week
+12.36%1 Month
-25.72%3 Month
-18.04%6 Month
-98.21%5 Year
-99.14%All Time

Cash Data

Unlock XFOR cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
306.36 M
EPS (TTM)
-0.79
P/E Ratio
-
Ent. Value
193.66 M
Total Shares
99.14 M
Float Shares
77.31 M
Insiders
24.29%
Institutions
82.32%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 3 topline data readout
mavorixafor
primary chronic neutropenia
Fast Track
Phase 3Small MoleculesHematology
Unlock every XFOR catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

XFOR Catalyst Timeline

Dated clinical, regulatory and corporate events for X4 Pharmaceuticals, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for X4 Pharmaceuticals, Inc.

146Total events
9Upcoming
45Tier-1 (high impact)
2018 to 2029Coverage

Upcoming catalysts 2

T2Enrollment Complete
Subscribe to view catalyst details
MavorixaforApproved
T2Trial Initiation
Subscribe to view catalyst details
MavorixaforApproved

Event history 50

●Quarterly UpdateCorporate
Reported third quarter 2026 financial results and corporate update
●R&D DayPresentation
X4 hosted virtual Investor Day highlighting mavorixafor PCN opportunity
▲Debt Royalty FinancingCorporate
X4 enters up to $150M senior secured term loan facility with K2 HealthVentures
●Equity OfferingCorporate
Inducement stock options granted to new employees (80,000 shares)
▲Type C MeetingMavorixaforApprovedFDA Meeting
Positive outcome from FDA Type C Meeting on revised 4WARD sample size and safety database
chronic neutropeniasource ↗
●R&D DayPresentation
X4 Pharmaceuticals management to participate in fireside chat at 2026 Wells Fargo Healthcare Conference
◆Enrollment UpdateTrial
Continued progress in enrolling global 4WARD Phase 3 Chronic Neutropenia trial
Chronic Neutropeniasource ↗
▲EU ApprovalMavorixaforApprovedEx-US Regulatory
European Commission approval of XOLREMDI (Mavorixafor) for WHIM syndrome
WHIM Syndromesource ↗
◆Enrollment CompleteMavorixaforApprovedTrial
4WARD Phase 3 trial enrollment completion expected by end of Q3 2026
chronic neutropeniasource ↗
◆Oral PresentationPresentation
X4 Pharmaceuticals to present at 2026 Jefferies Global Healthcare Conference
Unlock the full XFOR catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How XFOR actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2024-04-29Mavorixafor (CXCR4 inhibitor) PDUFA Date ApprovedPDUFA
Unlock 2 more XFOR historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 42%
Micro Cap
(rank 305 of 725)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Sep 2026; product lines: last four quarters to Sep 2026 (10-K and 10-Q))
ProductRevenuePrior periodChange
XOLREMDI
Showing 8 of 8 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Mavorixafor Small MoleculesNCT07902830Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia DisordersPhase 2 NOT YET_RECRUITING 40Jan 30, 2029
Mavorixafor Small MoleculesMarketedNCT03995108WHIM SyndromeApproved COMPLETED 31Dec 23, 2025
Mavorixafor Small MoleculesNCT04154488NeutropeniaPhase 3 COMPLETED 208Aug 27, 2024
Mavorixafor Small MoleculesNot countedNCT06858696Hepatic InsufficiencyPhase 1 COMPLETED 39Jan 12, 2026
Mavorixafor Small MoleculesNot countedNCT04274738Waldenstrom's MacroglobulinemiaPhase 1 COMPLETED 16Oct 31, 2022
X4P-001 Small MoleculesMarketedNCT03005327WHIM SyndromeApproved COMPLETED 8Jun 16, 2022
X4P-001 Small MoleculesNot countedNCT02667886Clear Cell Renal Cell CarcinomaPhase 1/2 COMPLETED 74Apr 14, 2022
X4P-001 Small MoleculesNot countedNCT02823405MelanomaPhase 1 COMPLETED 16Mar 15, 2018
Unlock the XFOR pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every XFOR program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
mavorixafor
BreakthroughPriorityFast Track+1
chronic neutropeniaPhase 22025-06-16significant increases in neutrophil counts; potential to reduce G-CSF use; clinically meaningful and durable increases in circulating neutrophils; able to reduce injectable G-CSF while maintaining ANC levels in the normal rangeRead MoreX4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)Read More
Scroll for more · summaries link to the source press release
Unlock every XFOR trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock XFOR insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Craig Adam RDirector, Officer (Executive Chairman)Buy 4,600 333,251 held$2.58 10/16/2026
Unlock the full XFOR insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC 1.6 % (-27.3 %) 23.11 M 7.97 M
Unlock every fund holding XFOR
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in XFOR
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see XFOR ownership
Insider and institutional ownership, quarter by quarter.

XFOR Short Interest

Shares sold short, counted twice a month.

10.31%
Short % of Float
of tradable shares sold short
8.0M
Shares Sold Short
+6.4% vs prior count
10.9 Very high
Days to Cover
trading days of normal volume to buy every short share back
734.2K
Avg Daily Volume
the average used for days to cover
Unlock XFOR short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock XFOR option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live XFOR option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock XFOR options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How XFOR ranks across every disease it competes in

Competitive Position is a premium feature
See how XFOR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

XFOR News

XFOR
Nov 4, 2026
XFORPhases
▼ -5.2%on this news

X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals reported its Q3 2026 financial results, highlighting progress in its 4WARD Phase 3 trial for mavorixafor. The company expects to complete enrollment of 126 participants by Q4 2026, with topline data anticipated in Q1 2028. Additionally, the new 4STEPS Phase 2b trial is set to begin in Q1 2027, aiming to evaluate G-CSF dosage reduction.

Read more →
XFOR
Nov 3, 2026
XFORConferences/Events

X4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026

X4 Pharmaceuticals announced its participation in three investment conferences in November 2026. The events include the Guggenheim Healthcare Innovation Conference, Stifel Healthcare Conference, and Jefferies London Healthcare Conference. The company focuses on therapies for rare hematology diseases and is conducting a pivotal Phase 3 trial for mavorixafor.

Read more →
XFOR
Oct 29, 2026
XFORPhases

X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day

X4 Pharmaceuticals hosted a virtual Investor Day to discuss mavorixafor's potential in treating primary chronic neutropenia (PCN). The company expects to complete enrollment for its 4WARD Phase 3 trial by Q4 2026 and initiate the 4STEPS Phase 2b trial in Q1 2027. Topline data from both trials is anticipated in Q1 2028, with a market opportunity estimated at 15,000 to 30,000 patients.

Read more →
XFOR
Oct 9, 2026
XFORConferences/Events

X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders

X4 Pharmaceuticals has announced a virtual Investor Day scheduled for October 29, 2026, focusing on mavorixafor as a treatment for chronic neutropenia. The event will include discussions on the ongoing Phase 3 4WARD clinical trial and plans for a Phase 2 trial in combination with G-CSF. Key opinion leaders will participate, providing expert insights into the treatment's potential.

Read more →
XFOR
Oct 8, 2026
XFORGeneral

X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures

X4 Pharmaceuticals has secured a senior debt facility of up to $150 million with K2 HealthVentures, enhancing its financial flexibility. The first tranche of $80 million has been used to repay existing loans. The company expects to complete enrollment in its Phase 3 4WARD trial by the end of 2026, with topline data anticipated in the first half of 2028.

Read more →
XFOR
Oct 1, 2026
XFORGeneral

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals announced the issuance of inducement awards under its 2019 Inducement Equity Incentive Plan to attract new employees. The awards consist of options to purchase 80,000 shares of common stock, with a ten-year term and an exercise price of $2.90 per share. These options will vest over four years, contingent on continued employment. This initiative aligns with Nasdaq Listing Rule 5635(c)(4).

Read more →
XFOR
Sep 9, 2026
XFORConferences/Events

X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference

X4 Pharmaceuticals announced that its management team will participate in a fireside chat at the 2026 Wells Fargo Healthcare Conference. The event is scheduled for Thursday, September 10, 2026, at 9:30 a.m. ET. Investors can access the live and archived webcast via the company website. The firm focuses on rare hematology diseases and commercializes mavorixafor.

Read more →
XFOR
Sep 8, 2026
XFORPhases
▼ -13.2%on this newsshared move

X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting

X4 Pharmaceuticals announced a positive outcome from its Type C meeting with the FDA regarding the 4WARD Phase 3 trial for mavorixafor. The FDA approved a reduction in the trial's sample size from 176 to 126 participants while maintaining statistical power for key endpoints. Enrollment is expected to complete by the end of 2026, with topline data anticipated in early 2028.

Read more →
XFOR
Aug 6, 2026
XFORGeneral
▲ +11.3%on this news

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals reported a net loss of $16.2 million for the second quarter of 2026. Cash reserves stood at $208.0 million as of June 30. The company also announced European Commission approval for XOLREMDI to treat WHIM syndrome. Management expects to update the FDA on the 4WARD trial sample size by the end of the third quarter.

Read more →
XFOR
Jul 1, 2026
XFORGeneral
▼ -12.5%on this newsshared move

X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors

X4 Pharmaceuticals appointed Kelly Gold to its Board of Directors effective July 1, 2026. She joins as an independent director and Audit Committee member. Gold currently serves as Chief Financial Officer at CAMP4 Therapeutics. The company stated her financial and scientific background supports its strategic priorities.

Read more →
XFOR
May 27, 2026
XFORConferences/Events

X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

X4 Pharmaceuticals will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026. The presentation will be accessible via a live and archived webcast on their website. X4 focuses on therapies for rare hematology diseases and is advancing mavorixafor, an approved treatment for WHIM syndrome, currently in a Phase 3 trial for chronic neutropenic disorders.

Read more →
XFOR
May 6, 2026
XFORGeneral

X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals reported its Q1 2026 financial results, highlighting progress in its 4WARD Phase 3 trial for mavorixafor, which is on track for enrollment completion by Q3 2026. The European Commission granted marketing authorization for XOLREMDI, the first treatment for WHIM syndrome in the EU. Despite a net loss of $20.2 million, the company maintains a strong cash position to support its operations through 2028.

Read more →
XFOR
Apr 29, 2026
XFORFDA Updates

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

X4 Pharmaceuticals has received European Commission approval for XOLREMDI (mavorixafor), the first treatment for WHIM syndrome in the EU. This authorization follows a positive opinion from the EMA and is aimed at providing a new therapeutic option for patients. The company is also conducting a global Phase 3 trial for chronic neutropenia, further exploring mavorixafor's potential benefits.

Read more →
XFOR
Mar 17, 2026
XFORFDA Updates
▲ +18.8%on this news

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

X4 Pharmaceuticals reported its financial results for Q4 and full year 2025, highlighting a positive opinion from the European Medicines Agency for mavorixafor's marketing authorization in the EU. The company is on track to complete enrollment in its pivotal 4WARD Phase 3 trial for chronic neutropenia by Q3 2026. Despite a significant operating loss, X4 has a cash runway through 2028, allowing continued development of its therapies.

Read more →
XFOR
Mar 4, 2026
XFORConferences/Events
▲ +5.1%on this news· ran to +25% by day 3

X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference

X4 Pharmaceuticals will participate in a fireside chat at the Leerink Global Healthcare Conference on March 11, 2026. The event will showcase the company's commitment to improving the lives of patients with rare hematology diseases. X4 is currently conducting a pivotal Phase 3 trial for its drug mavorixafor, which has received FDA Fast Track designation.

Read more →
XFOR
Mar 3, 2026
XFORGeneral

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 2, 2026

X4 Pharmaceuticals announced the issuance of inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. The awards, consisting of options to purchase 24,000 shares of common stock, are intended to attract new talent. The options have a ten-year term and an exercise price equal to the stock's closing price on the grant date. X4 is known for its focus on therapies for rare hematology diseases.

Read more →

About X4 Pharmaceuticals, Inc.

Boston, MA 45 employees x4pharma.com
Headquarters61 NORTH BEACON STREET, BOSTON, MA, 02134
BIOPHARMAWATCH ELITE
Trade the next XFOR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime